ClinicalTrials.gg
RecruitingNCT07451054Updated Aug 10, 2026

CD45BE-HSPC + CART-45 Cells

A Phase 1 interventional study of CART-45 cells and CD45BE-HSPC in B-Cell Non-Hodgkin Lymphoma (NHL), Richter's Transformation and T-Cell Non-Hodgkin Lymphoma, sponsored by University of Pennsylvania. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by University of Pennsylvania · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 399 studies in Lymphoma, B-Cell with a site in United States — 91 open to participants now, 157 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Planned enrollment
167th of 381
42 · median 37
Started
2026
with 20 others
Phase 1
162 of 399
35 open now
Primary completion
2051-07
later than 156 of 156 live
Registered
385th of 399
by date

Among the 399 studies in Lymphoma, B-Cell with a site in United States, this one is the 167th largest by planned enrollment of the 381 interventional ones that give a count, is one of 21 that started in 2026, is one of 162 in phase 1, reaches primary completion later than 156 of the 156 other live ones, and was the 385th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

91 of the 399 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

85 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 399 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as "CD45BE-HSPC") in patients with relapsed or refractory hematologic malignancies.

03

Conditions studied

  • B-Cell Non-Hodgkin Lymphoma (NHL)
  • Richter's Transformation
  • T-Cell Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Signed form 2. Male or females age ≥ 18 years 3. Disease-Specific Criteria

a. B-cell Non-Hodgkin Lymphoma (B-cell NHL)- including the following sub-types:

i. Patients with any of the following large B-cell lymphoma diagnoses who meet the prior treatment criteria outlined below: Diffuse Large B-cell Lymphoma not otherwise specified (DLBCL NOS); Primary Cutaneous DLBCL; Primary Mediastinal (thymic) Large B-cell Lymphoma; ALK+ Anaplastic Large B-cell Lymphoma; High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 rearrangements (i.e., "Double or Triple Hit"); High-grade B-cell Lymphoma, NOS; T-cell Rich B-cell Lymphoma; Transformed Follicular Lymphoma; or any aggressive B-cell lymphoma arising from indolent lymphoma.

1. Patients must have either failed/ after, or be ineligible for, prior commercial CAR T cell therapy; AND 2. Relapsed/refractory disease after at least 2 prior lines of appropriate therapy.

ii. Follicular Lymphoma

  1. Patients must have either failed/relapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND
  2. Relapsed/refractory disease after at least 2 (not including a single agent monoclonal antibody therapy).

iii. Mantle Cell Lymphoma

  1. Patients must have either failed/relapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND
  2. Relapsed/refractory disease after at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (TKI) inhibitor. Single-agent monoclonal antibody therapy does not count towards prior lines of therapy.

    iv. Marginal Zone Lymphoma- relapsed/refractory disease after at least 2 prior lines of appropriate therapy, including a Bruton tyrosine kinase (TKI) inhibitor. Note: Single-agent monoclonal antibody therapy does not count towards prior lines of therapy.

    b. T-cell Non-Hodgkin Lymphoma (T-cell NHL)

    i. or cytologically confirmed relapsed or refractory (r/r) mature aggressive T- and NK-cell neoplasms as defined in the 5th edition of the WHO Classification of Hematolymphoid tumors, which includes any of the following diagnoses:

    • Peripheral T-cell Lymphoma, NOS (PTCL-NOS);
    • Nodal T-cell Lymphomas with T Follicular Helper [TFH] Phenotype, including Follicular T cell Lymphoma, Angioimmunoblastic Lymphoma, or Anaplastic Large Cell Lymphoma (ALCL);
    • ALK+ or ALK-, Enteropathy-Associated T-cell Lymphoma (EATL);
    • Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL);
    • Extranodal NK/T-cell Lymphoma;
    • Primary Cutaneous T-cell Lymphoma (CTCL);
    • Transformed Mycosis Fungoides (tMF) without blood involvement;
    • Primary Cutaneous Aggressive Epidermotropic CD8+ Cytotoxic T-Cell Lymphoma;
    • Subcutaneous Panniculitis-like T-cell Lymphoma.

    ii. Must have received at least one prior line of systemic therapy for their lymphoma. Additional prior treatment provisions required for the following indications:

1. Participants with Anaplastic Large Cell Lymphoma (ALCL) must have received prior Brentuximab vedotin, unless .

2. Participants with Subcutaneous Panniculitis-like T-cell Lymphoma or Transformed Mycosis Fungoides (tMF) must have received at least 2 prior lines of systemic therapy.

c. Hodgkin Lymphoma (HL)

i. Patients with histologically proven classical Hodgkin Lymphoma that is 5 positive by IHC or flow cytometry by a CLIA certified laboratory; AND

ii. Relapsed/refractory disease after at least 2 prior lines of therapy which must include the following:

  1. Brentuximab vedotin and (unless contraindicated); AND
  2. stem cell transplant (unless patient has chemorefractory disease to salvage treatment) d. Large Cell Transformation of CLL (Richter's Transformation) i. Patients must be primary refractory or received at least 1 prior line of treatment for Richter's Transformation.

4. Patients are appropriate candidates for autologous HSCT as per physician-investigator clinical discretion

5. Patients with relapsed disease after prior allogeneic SCT must meet the following criteria:

a. Have no active and require no

b. Are more than 6 months from transplant at the time of physician-investigator confirmation of eligibility

6. Adequate organ function defined as:

  1. Serum creatinine ≤ 1.5x or estimated ≥ 35 mL/min and not on dialysis
  2. /AST ≤ 3 x ULN
  3. Direct ≤ 2.0 mg/dl; for patients with Gilbert's syndrome direct bilirubin must be ≤ 3.0 mg/dl
  4. (LVEF) ≥ 40% confirmed by ECHO/MUGA
  5. DLCO > 45% predicted value; adjusted for level of
  6. Must have minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen > 92% on room air 7. Performance Status 0-1

Exclusion criteria

Exclusion Criteria:

  1. Active or infection
  2. Any active, uncontrolled infection.
  3. Class III/IV cardiovascular disability according to the Classification.
  4. Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility.
  5. Severe, active co-morbidity that, in the opinion of the physician-investigator, would preclude participation in this study.
  6. Prior or concurrent whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the regimen.
  7. Active acute or chronic requiring systemic therapy.
  8. Dependence on systemic or medications. For additional details regarding use of steroid and immunosuppressant medications.
  9. Active CNS involvement. Patients with a history of CNS involvement that was successfully treated are eligible. A CNS evaluation is only required for eligibility if a subject is experiencing signs/symptoms of CNS involvement.
  10. Patients with evidence of a circulating T-cell malignancy as measured by flow cytometry.
  11. History of allergy or to study product (human serum albumin, DMSO, and Dextran 40).
  12. Active disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.
  13. Pregnant or nursing (lactating) patients. Participants of must agree to use acceptable methods.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Cohort A: B-cell Non-Hodgkin Lymphoma (B-cell NHL), Richter's Transformation (RT)

    Biological: CART-45 cells · Biological: CD45BE-HSPC

  • Experimental
    Cohort B: T-cell Non-Hodgkin Lymphoma (T-cell NHL), Hodgkin Lymphoma (HL)

    Biological: CART-45 cells · Biological: CD45BE-HSPC

Interventions

  • BiologicalCART-45 cells

    Autologous base edited anti-CD45 CAR T cells

  • BiologicalCD45BE-HSPC

    CD45 base edited hematopoietic stem and progenitor cells

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events as assessed by CTCAE v6.0

    Type, frequency and severity of adverse events as assessed by CTCAE V6.0. Each disease-specific cohort will be analyzed separately.

    Time frame: Up to 15 years post infusion

  2. Occurrence of dose-limiting toxicities (DLTs)

    Unacceptable toxicity as defined by the protocol. DLTs will be evaluated separately by each disease-specific cohort.

    Time frame: 28 days post-CART-45 infusion

  3. Identification of the maximum tolerated dose (MTD)

    Selected based on an isotonic regression model. The MTD will be established separately by disease-specific cohort

    Time frame: 28 days post-CART-45 infusion

  4. Identification of a recommended dose for expansion (RDE)

    Evaluated by Cohort/dose level using a multi-criteria decision analysis.

    Time frame: 3 months post-CART-45 infusion

Secondary outcomes

  1. Proportion of CD45BE-HSPC products that fail to meet the product release criteria

    Calculated based on the proportion of subjects with CD45BE-HSPC products that fail to meet the product release criteria, out of the number of subjects in whom manufacturing was attempted.

    Time frame: 3 months

  2. Proportion of CART-45 products that fail to meet the product release criteria

    Calculated based on the proportion of subjects with CART-45 products that fail to meet the product release criteria, out of the number of subjects in whom manufacturing was attempted.

    Time frame: 3 months

  3. Proportion of CD45BE-HSPC products that fail to meet the protocol-defined dose

    Calculated based on the proportion of subjects with CD45BE-HSPC products that fail to meet the assigned dose, out of the number of subjects in whom manufacturing was attempted.

    Time frame: 3 months

  4. Proportion of CART-45 products that fail to meet the assigned dose.

    Calculated based on the proportion of subjects with CART-45 products that fail to meet the assigned dose, out of the number of subjects in whom manufacturing was attempted.

    Time frame: 3 months

  5. Evaluate study feasibility

    Proportion of eligible patients who receive both investigational products as planned; by individual disease-specific cohort and in aggregate.

    Time frame: 3 months

  6. Engraftment of CD45BE-HSPC

    Number of subjects with engraftment of CD45BE-HSPC.

    Time frame: 28 days after treatment

  7. Overall survival (OS)

    Duration of time from CD45BE-HSPC infusion (Day 0) to the date of death, for any reason

    Time frame: Up to 15 years after last CART-45 Cells administration

  8. Overall Response/Remission Rate (ORR)

    Proportion of subjects with CR or PR at Month 3 as compared to baseline.

    Time frame: Up to 12 months following CART-45 administration

  9. Best Overall Response (BOR)

    Proportion of subjects with a best objective disease response of CR or PR recorded between Month 3 and the end of primary follow-up (Month 12); or start of new anticancer therapy, whichever comes first.

    Time frame: Up to 12 months following CART-45 administration

  10. Duration of Response (DOR)

    Time from the date when the response criteria of CR or PR is first met (at or following Month 3), to the date of confirmed disease progression, death, or other censoring event as described below.

    Time frame: Up to 12 months following CART-45 administration

  11. Progression-Free Survival (PFS)

    The duration of time from the CD45BE-HSPC transplant (Day 0) to the date of confirmed disease progression or death, whichever occurs first. Otherwise, PFS will be censored at the date of the last response assessment, date of new anti-cancer treatment is initiated (including CART-45 retreatment) or the data cut-off date; whichever occurs first.

    Time frame: Up to 15 years after product administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jul 2051, 299 months after the start.

Of 117 non-industry phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 75. This study's planned 299 months is above that.

Counting every sponsor, half of 208 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 5, 2026
StartActual
Aug 5, 2026
Primary completionEst.
Jul 2051
CompletionEst.
Jul 2051
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07451054
Responsible party
Sponsor
First posted
Mar 5, 2026
Start date
Aug 5, 2026
Primary completion
Jul 2051 (estimated)
Completion
Jul 2051 (estimated)
Last update
Aug 10, 2026

Study contacts

Abramson Cancer Center Clinical Trials Service
Contact
PMCancerResearch@Pennmedicine.upenn.edu
215-349-8245
Noelle Frey, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion